Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 20, 2017
Pharmacy Choice - Pharmaceutical News - FDA Grants PMA Approval for Hologic's Aptima Hepatitis C Quant Dx Assay - November 20, 2017

Pharmacy News Article

 2/15/17 - FDA Grants PMA Approval for Hologic's Aptima Hepatitis C Quant Dx Assay

MARLBOROUGH, Mass., Feb. 15, 2017 /PRNewswire/ Hologic, Inc. (Nasdaq: HOLX) announced today that the United States Food and Drug Administration (FDA) has granted PMA approval for the Company's hepatitis C virus (HCV) assay for quantitation of HCV viral load and confirming active HCV infection on the fully automated Panther system.

"HCV therapeutic options continue to evolve rapidly with highly effective antiviral medications that are transforming treatment of the disease, with cure rates above 90%," said Tom West, president, Diagnostic Solutions Division at Hologic. "The expanded use of the Aptima HCV Quant Dx assay to confirm active HCV infection in addition to viral load quantitation will help physicians more quickly determine the best treatment options and help improve patient care."

The Aptima HCV Quant Dx assay uses real-time transcription-mediated amplification (TMA), which provides highly sensitive and specific performance for diagnostic use, as well as reliable quantitation for determination of sustained antiviral response across all major genotypes and a wide linear range. The assay runs on the Panther system, which provides full sample to answer automation and substantially reduces hands-on time with random and continuous access.

The Aptima HCV Quant Dx assay joins a growing list of tests available on the Panther system in the U.S. market. In addition to an HIV-1 (human immunodeficiency virus) viral load assay, the Panther menu includes tests for sexually transmitted infections chlamydia, gonorrhea, trichomonas and human papillomavirus (HPV).

"Menu consolidation is increasingly important to clinical laboratories in their efforts to increase efficiency of operations," said West. "Expanding the range of assays that can be run on the Panther system with offerings in virology, in addition to women's health, will help our customers reach their goals."

Hologic has a long-term legacy in the virology space, beginning two decades ago and spanning development of nucleic acid tests to screen the blood supply for HIV, HCV and HBV, an expertise that was applied to the development of the viral load portfolio on the Panther system.

In Europe, the Aptima HCV Quant Dxassay is CE-IVD marked for diagnostic and viral load monitoring, as is the Aptima HIV-1 Quant Dx assay. The Aptima HBV (hepatitis B) Quant assay is CE-IVD marked for viral load monitoring but is not currently approved for sale in the United States. To learn more about the Aptima Quant assays available in the United States, please visit

About Hologic
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure. For more information on Hologic, visit

Hologic Forward-Looking Statements
This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic's diagnostic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

Hologic, The Science of Sure, Aptima and Panther are registered trademarks of Hologic, Inc. in the United States and/or other countries.

Hologic Investor Contact
Michael Watts
Vice President, Investor Relations and Corporate Communications
+1 (858) 410-8588

Hologic Media Contact
Jane Mazur
Senior Director, Divisional Communications
+1 (585) 355-5978

To view the original version on PR Newswire, visit:

SOURCE Hologic, Inc.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Nov 20: Obesity Management: Overview of Pharmacotherapy
Last Chance
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Last Chance
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Nov 28: An Integrative Approach to Managing Arthritis
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement